Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)

Celalettin Ustun; Elizabeth Morgan; Erica E.M. Moodie; Sheeja Pullarkat; Cecilia Yeung; Sigurd Broesby-Olsen; Robert Ohgami; Young Kim; Wolfgang Sperr; Hanne Vestergaard; Dong Chen; Philip M. Kluin; Michelle Dolan; Krzysztof Mrózek; David Czuchlewski; Hans Peter Horny; Tracy I. George; Thomas Kielsgaard Kristensen; Nam K. Ku; Cecilia Arana Yi; Michael Boe Møller; Guido Marcucci; Linda Baughn; Ana Iris Schiefer; J. R. Hilberink; Vinod Pullarkat; Ryan Shanley; Jessica Kohlschmidt; Janie Coulombe; Amandeep Salhotra; Lori Soma; Christina Cho; Michael A. Linden; Cem Akin; Jason Gotlib; Gregor Hoermann; Jason Hornick; Ryo Nakamura; Joachim Deeg; Clara D. Bloomfield; Daniel Weisdorf; Mark R. Litzow; Peter Valent; Gerwin Huls; Miguel Angel Perales; Gautam Borthakur

doi:10.1002/cam4.1733

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)

Celalettin Ustun, Elizabeth Morgan, Erica E.M. Moodie, Sheeja Pullarkat, Cecilia Yeung, Sigurd Broesby-Olsen, Robert Ohgami, Young Kim, Wolfgang Sperr, Hanne Vestergaard, Dong Chen, Philip M. Kluin, Michelle Dolan, Krzysztof Mrózek, David Czuchlewski, Hans Peter Horny, Tracy I. George, Thomas Kielsgaard Kristensen, Nam K. Ku, Cecilia Arana YiMichael Boe Møller, Guido Marcucci, Linda Baughn, Ana Iris Schiefer, J. R. Hilberink, Vinod Pullarkat, Ryan Shanley, Jessica Kohlschmidt, Janie Coulombe, Amandeep Salhotra, Lori Soma, Christina Cho, Michael A. Linden, Cem Akin, Jason Gotlib, Gregor Hoermann, Jason Hornick, Ryo Nakamura, Joachim Deeg, Clara D. Bloomfield, Daniel Weisdorf, Mark R. Litzow, Peter Valent, Gerwin Huls, Miguel Angel Perales, Gautam Borthakur

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Background: Although the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse. Methods: Eleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22). Results: Complete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease-free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P < 0.0001). Low- vs high-risk OS at 2 years was 89% vs 51% (P < 0.0001). Conclusions: I-CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low-risk I-CBFit score).

Original language	English (US)
Pages (from-to)	4447-4455
Number of pages	9
Journal	Cancer medicine
Volume	7
Issue number	9
DOIs	https://doi.org/10.1002/cam4.1733
State	Published - Sep 2018

Keywords

KIT mutation
acute myeloid leukemia
core-binding factor
disease-free survival
predictive value
relapse
scoring system

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1002/cam4.1733

Cite this

Ustun, C., Morgan, E., Moodie, E. E. M., Pullarkat, S., Yeung, C., Broesby-Olsen, S., Ohgami, R., Kim, Y., Sperr, W., Vestergaard, H., Chen, D., Kluin, P. M., Dolan, M., Mrózek, K., Czuchlewski, D., Horny, H. P., George, T. I., Kristensen, T. K., Ku, N. K., ... Borthakur, G. (2018). Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). Cancer medicine, 7(9), 4447-4455. https://doi.org/10.1002/cam4.1733

Ustun, C, Morgan, E, Moodie, EEM, Pullarkat, S, Yeung, C, Broesby-Olsen, S, Ohgami, R, Kim, Y, Sperr, W, Vestergaard, H, Chen, D, Kluin, PM, Dolan, M, Mrózek, K, Czuchlewski, D, Horny, HP, George, TI, Kristensen, TK, Ku, NK, Yi, CA, Møller, MB, Marcucci, G, Baughn, L, Schiefer, AI, Hilberink, JR, Pullarkat, V, Shanley, R, Kohlschmidt, J, Coulombe, J, Salhotra, A, Soma, L, Cho, C, Linden, MA, Akin, C, Gotlib, J, Hoermann, G, Hornick, J, Nakamura, R, Deeg, J, Bloomfield, CD, Weisdorf, D, Litzow, MR, Valent, P, Huls, G, Perales, MA & Borthakur, G 2018, 'Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)', Cancer medicine, vol. 7, no. 9, pp. 4447-4455. https://doi.org/10.1002/cam4.1733

@article{b68fb0b0db3f4429a77518b8ecdd87ca,

title = "Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)",

abstract = "Background: Although the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse. Methods: Eleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22). Results: Complete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease-free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P < 0.0001). Low- vs high-risk OS at 2 years was 89% vs 51% (P < 0.0001). Conclusions: I-CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low-risk I-CBFit score).",

keywords = "KIT mutation, acute myeloid leukemia, core-binding factor, disease-free survival, predictive value, relapse, scoring system",

author = "Celalettin Ustun and Elizabeth Morgan and Moodie, {Erica E.M.} and Sheeja Pullarkat and Cecilia Yeung and Sigurd Broesby-Olsen and Robert Ohgami and Young Kim and Wolfgang Sperr and Hanne Vestergaard and Dong Chen and Kluin, {Philip M.} and Michelle Dolan and Krzysztof Mr{\'o}zek and David Czuchlewski and Horny, {Hans Peter} and George, {Tracy I.} and Kristensen, {Thomas Kielsgaard} and Ku, {Nam K.} and Yi, {Cecilia Arana} and M{\o}ller, {Michael Boe} and Guido Marcucci and Linda Baughn and Schiefer, {Ana Iris} and Hilberink, {J. R.} and Vinod Pullarkat and Ryan Shanley and Jessica Kohlschmidt and Janie Coulombe and Amandeep Salhotra and Lori Soma and Christina Cho and Linden, {Michael A.} and Cem Akin and Jason Gotlib and Gregor Hoermann and Jason Hornick and Ryo Nakamura and Joachim Deeg and Bloomfield, {Clara D.} and Daniel Weisdorf and Litzow, {Mark R.} and Peter Valent and Gerwin Huls and Perales, {Miguel Angel} and Gautam Borthakur",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",

year = "2018",

month = sep,

doi = "10.1002/cam4.1733",

language = "English (US)",

volume = "7",

pages = "4447--4455",

journal = "Cancer medicine",

issn = "2045-7634",

publisher = "John Wiley and Sons Ltd",

number = "9",

}

TY - JOUR

T1 - Core-binding factor acute myeloid leukemia with t(8;21)

T2 - Risk factors and a novel scoring system (I-CBFit)

AU - Ustun, Celalettin

AU - Morgan, Elizabeth

AU - Moodie, Erica E.M.

AU - Pullarkat, Sheeja

AU - Yeung, Cecilia

AU - Broesby-Olsen, Sigurd

AU - Ohgami, Robert

AU - Kim, Young

AU - Sperr, Wolfgang

AU - Vestergaard, Hanne

AU - Chen, Dong

AU - Kluin, Philip M.

AU - Dolan, Michelle

AU - Mrózek, Krzysztof

AU - Czuchlewski, David

AU - Horny, Hans Peter

AU - George, Tracy I.

AU - Kristensen, Thomas Kielsgaard

AU - Ku, Nam K.

AU - Yi, Cecilia Arana

AU - Møller, Michael Boe

AU - Marcucci, Guido

AU - Baughn, Linda

AU - Schiefer, Ana Iris

AU - Hilberink, J. R.

AU - Pullarkat, Vinod

AU - Shanley, Ryan

AU - Kohlschmidt, Jessica

AU - Coulombe, Janie

AU - Salhotra, Amandeep

AU - Soma, Lori

AU - Cho, Christina

AU - Linden, Michael A.

AU - Akin, Cem

AU - Gotlib, Jason

AU - Hoermann, Gregor

AU - Hornick, Jason

AU - Nakamura, Ryo

AU - Deeg, Joachim

AU - Bloomfield, Clara D.

AU - Weisdorf, Daniel

AU - Litzow, Mark R.

AU - Valent, Peter

AU - Huls, Gerwin

AU - Perales, Miguel Angel

AU - Borthakur, Gautam

PY - 2018/9

Y1 - 2018/9

N2 - Background: Although the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse. Methods: Eleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22). Results: Complete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease-free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P < 0.0001). Low- vs high-risk OS at 2 years was 89% vs 51% (P < 0.0001). Conclusions: I-CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low-risk I-CBFit score).

AB - Background: Although the prognosis of core-binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no validated widely accepted scoring system to predict patient subsets with higher risk of relapse. Methods: Eleven centers in the US and Europe evaluated 247 patients with t(8;21)(q22;q22). Results: Complete remission (CR) rate was high (92.7%), yet relapse occurred in 27.1% of patients. A total of 24.7% of patients received alloHCT. The median disease-free (DFS) and overall (OS) survival were 20.8 and 31.2 months, respectively. Age, KIT D816V mutated (11.3%) or nontested (36.4%) compared with KIT D816V wild type (52.5%), high white blood cell counts (WBC), and pseudodiploidy compared with hyper- or hypodiploidy were included in a scoring system (named I-CBFit). DFS rate at 2 years was 76% for patients with a low-risk I-CBFit score compared with 36% for those with a high-risk I-CBFit score (P < 0.0001). Low- vs high-risk OS at 2 years was 89% vs 51% (P < 0.0001). Conclusions: I-CBFit composed of readily available risk factors can be useful to tailor the therapy of patients, especially for whom alloHCT is not need in CR1 (ie, patients with a low-risk I-CBFit score).

KW - KIT mutation

KW - acute myeloid leukemia

KW - core-binding factor

KW - disease-free survival

KW - predictive value

KW - relapse

KW - scoring system

UR - http://www.scopus.com/inward/record.url?scp=85052656740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052656740&partnerID=8YFLogxK

U2 - 10.1002/cam4.1733

DO - 10.1002/cam4.1733

M3 - Article

C2 - 30117318

AN - SCOPUS:85052656740

SN - 2045-7634

VL - 7

SP - 4447

EP - 4455

JO - Cancer medicine

JF - Cancer medicine

IS - 9

ER -

Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this